It is no secret that the accessibility of gene therapies is a widely debated topic. Therapies continue to be brought to market at inaccessibly high price points, hindering access to the technology for the very patient population the products are designed for.
Safety concerns are creating a relatively early-stage bottleneck in the progress of gene therapies to market. However, the conversation around...